Anti-epidermal growth factor receptor antibody cetuximab in refractory or relapsed multiple myeloma: a phase II prospective clinical trial

Tresckow, Bastian von; Boell, Boris; Eichenauer, Dennis A.; Beschorner, Denissa; Knop, Stefan; Goebeler, Maria-Elisabeth; Chemnitz, Jens M.; Hallek, Michael; Engert, Andreas; Huebel, Kai

doi:10.3109/10428194.2013.809074

Cited by 7 publications

(4 citation statements)

References 6 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Many antibodies are extensively being explored for the treatment of MM (Table 1). Phase II (NCT01524978) [77] Antibodies have also been used to deliver cytotoxic drugs and nanoparticles (NPs) to cancer cells. Antibody-Drug Conjugates (ADCs) use the specificity of the antibody towards any specified target, and the cell killing capacityof the cytotoxic agent that has been chemically conjugated to the antibody (Nejadmoghaddam et al, 2019) [78].…”

Section: Antibody Therapymentioning

confidence: 99%

Multiple Myeloma: Therapeutic Delivery of Antibodies and Aptamers

et al. 2021

View full text Add to dashboard Cite

Multiple myeloma is the second most common hematological malignancy in adults, accounting for 2% of all cancer-related deaths in the UK. Current chemotherapy-based regimes are insufficient, as most patients relapse and develop therapy resistance. This review focuses on current novel antibody- and aptamer-based therapies aiming to overcome current therapy limitations, as well as their respective limitations and areas of improvement. The use of computer modeling methods, as a tool to study and improve ligand-receptor alignments for the use of novel therapy development will also be discussed, as it has become a rapid, reliable and comparatively inexpensive method of investigation.

show abstract

Section: Antibody Therapymentioning

confidence: 99%

Multiple Myeloma: Therapeutic Delivery of Antibodies and Aptamers

et al. 2021

View full text Add to dashboard Cite

show abstract

“…However, no ORs were detected in combination with dexamethasone. 47% of patients achieved stable disease [ 36 ].…”

Section: Main Immunotherapy Strategies Currently Being Used or Tesmentioning

confidence: 99%

Immunotherapy: A Novel Era of Promising Treatments for Multiple Myeloma

Castellà

Larrea

Martín-Antonio

2018

IJMS

View full text Add to dashboard Cite

Multiple myeloma (MM) remains an incurable hematological malignancy characterized by clonal proliferation of malignant plasma cells in bone marrow. In the last 20 years, the introduction of autologous stem cell transplantation, followed by proteasome inhibitors and immunomodulatory agents, increased the survival of MM patients by 50%. However, still a high proportion of patients relapse and become refractory, especially, high-risk patients with adverse cytogenetics where these treatment combinations have shown limited benefit. Therefore, novel strategies, such as immunotherapy, have been developed in the last few years to help improve the survival of these patients. Immunotherapy treatments include a high number of different strategies used to attack the tumor cells by using the immune system. Here, we will review the most successful immunotherapy strategies published up to date in patients with relapsed or refractory (R/R) MM, including monoclonal antibodies targeting specific antigens on the tumor cells, antibodies combined with cytotoxic drugs or Antibodies Drug Conjugates, immune checkpoint inhibitors which eliminate the barriers that damper immune cells and prevent them from attacking tumor cells, bi-specific T-cell engagers antibodies (BiTEs), bi-specific antibodies and the infusion of chimeric antigen receptor-modified T cells. We overview the results of clinical studies that have been presented up to date and also review pre-clinical studies describing potential novel treatments for MM.

show abstract

“…At a mechanistic level, the study by Zhang et al presents the theme that TJP1 regulates response to proteasome inhibition through downstream mediators, which so far have not been viewed as main components of the pathophysiology of myeloma (e.g., EGF/EGFR) more broadly, or of PSI resistance more specifically (e.g., JAK/STAT3 signaling). With some notable exceptions (e.g., Mahtouk et al, 2004;Walker et al, 2013), receptors and ligands of the epidermal growth factor (EGF) superfamily have attracted limited interest as potential players in the pathophysiology of myeloma, possibly due to the paucity of evidence for anti-myeloma activity in clinical trials of agents targeting EGFR (von Tresckow et al, 2014;Kovacs et al, 2006). Perhaps influenced by its name and the notion that tight junctions have been typically viewed as critical morphological and functional components in epithelia, and not the lymphocytic/plasma cell lineage, the myeloma field may have overlooked TJP1.…”

mentioning

confidence: 99%

“…The findings of Zhang et al also raise important questions regarding the therapeutic potential of inhibiting EGFR or JAK signaling in multiple myeloma. Therapeutic agents against these targets have been previously tested clinically in multiple myeloma, e.g., combinations of the anti-EGFR monoclonal antibody cetuximab (von Tresckow et al, 2014) or the JAK inhibitor ruxolitinib (clinical trial NCT00639002) with dexamethasone, as well as single-agent treatment with kinase inhibitors that target EGFR (e.g., ZD6474) (Kovacs et al, 2006). However, major clinical responses were not observed in these studies.…”

mentioning

confidence: 99%